Alnylam Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALNY Nasdaq 2836 www.alnylam.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alnylam Pharmaceuticals, Inc.

Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial - Sep 19th, 2026 7:01 pm
RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics - Sep 18th, 2026 4:42 am
Is Alnylam (ALNY) Quietly Repricing Its RNAi Risk Profile Amid Oligonucleotide Market Optimism? - Sep 15th, 2026 1:18 pm
Slate Medicines Names Kenneth Koblan as Chief Scientific Officer - Sep 15th, 2026 9:18 am
Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics - Sep 15th, 2026 3:58 am
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture - Sep 15th, 2026 3:04 am
Alger Russell Innovation Index Updates for Third Quarter 2026 - Sep 14th, 2026 10:53 am
Here’s Why Alnylam Pharmaceuticals (ALNY) Declined - Sep 10th, 2026 5:44 am
Hereditary Transthyretin Amyloidosis Market Insight, Epidemiology, and Market Forecast - 2036 Now Available Reveals Why a $3B Market Is Racing Toward a One-Time Curative Gene-Editing Therapy - Sep 4th, 2026 2:02 am
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue? - Sep 2nd, 2026 9:30 am
Alnylam to Webcast Presentations at Upcoming September Investor Conferences - Sep 2nd, 2026 6:00 am
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects - Sep 1st, 2026 8:56 am
Alnylam's Latest Data Strengthen Outlook for Nucresiran, TRITON-CM, Oppenheimer Says - Aug 31st, 2026 9:40 am
Inceptive CEO Jakob Uszkoreit on Designing Medicines That Work Like Life Itself - Aug 31st, 2026 6:48 am
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings - Aug 30th, 2026 6:23 am
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY - Aug 28th, 2026 3:18 pm
Alnylam stock drops on rival heart trial: Why analysts see core business safe - Aug 28th, 2026 6:54 am
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease - Aug 28th, 2026 4:58 am
Moderna Stock Carries A Market Value Its Revenue Does Not Support - Aug 26th, 2026 9:13 am
BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum - Aug 25th, 2026 11:36 am